---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000740"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:06:22.962899+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coherus amends loan with Pharmakon; to prepay $175M, reduce interest ~70%

## Summary
- After closing ophthalmology divestiture to Sandoz, Coherus will prepay $175M of $250M loan principal, leaving $75M residual.
- Revenue covenant reduced to $125M under amended loan agreement with Pharmakon Advisors.
- Projected annual interest expense on term loan reduced by approximately 70%.
- Prepayment expected in Q2 2024; strengthens balance sheet for oncology growth.
- Amendment also provides consent and releases collateral tied to Sandoz transaction.

## SEC filing metadata
- accession: 0001558370-24-000740
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024000740/0001558370-24-000740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024000740/chrs-20240205x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000740
- JSON: https://secwatch.observer/filing/0001558370-24-000740.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000740.txt

## Key facts
- Material Agreements
  Coherus Oncology, Inc. amended Consent, Partial Release and Third Amendment to Loan Agreement with Biopharma Credit PLC, BPCR Limited Partnership, Biopharma Credit Investments V (MASTER) LP valued at $175,000,000 (effective 2024-02-05).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Biopharma Credit PLC, BPCR Limited Partnership, Biopharma Credit Investments V (MASTER) LP
  - Value: $175,000,000
  - Effective: 2024-02-05
  source text: On February 5, 2024, Coherus BioSciences, Inc. (the “Company”), as borrower and on behalf of itself and certain of its subsidiaries, entered into a Consent, Partial Release and Third Amendment to Loan Agreement (the “Consent and Amendment”) with Biopharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (the “Collateral Agent”), BPCR Limited Partnership, a limited partnership established under the laws of England and Wales, as a lender (“BPCR”), and Biopharma Credit Investments V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a lender, and together with as BPCR, each, a “Lender” and collectively, the “Lenders”), pursuant to which the Lenders and the Collateral Agent provided certain consents, and released certain assets and subsidiaries of the Company from their obligations under the Existing Loan Agreement and the other loan documents in connec
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837024000740/0001558370-24-000740-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.